Cargando…

IgM and IgG Immunoreactivity of SARS-CoV-2 Recombinant M Protein

Diagnostic evaluation of specific antibodies against the SARS-CoV-2 virus is mainly based on spike (S) and nucleocapsid (N) proteins. Despite the critical functions in virus infection and contribution to the pattern of immunodominance in COVID-19, exploitation of the most abundant membrane (M) prote...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopandić, Zorana, Protić-Rosić, Isidora, Todorović, Aleksandra, Glamočlija, Sofija, Gnjatović, Marija, Ćujic, Danica, Gavrović-Jankulović, Marija
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125631/
https://www.ncbi.nlm.nih.gov/pubmed/34066920
http://dx.doi.org/10.3390/ijms22094951
_version_ 1783693560925650944
author Lopandić, Zorana
Protić-Rosić, Isidora
Todorović, Aleksandra
Glamočlija, Sofija
Gnjatović, Marija
Ćujic, Danica
Gavrović-Jankulović, Marija
author_facet Lopandić, Zorana
Protić-Rosić, Isidora
Todorović, Aleksandra
Glamočlija, Sofija
Gnjatović, Marija
Ćujic, Danica
Gavrović-Jankulović, Marija
author_sort Lopandić, Zorana
collection PubMed
description Diagnostic evaluation of specific antibodies against the SARS-CoV-2 virus is mainly based on spike (S) and nucleocapsid (N) proteins. Despite the critical functions in virus infection and contribution to the pattern of immunodominance in COVID-19, exploitation of the most abundant membrane (M) protein in the SARS-CoV-2 serology tests is minimal. This study investigated the recombinant M protein’s immunoreactivity with the sera from COVID-19 convalescents. In silico designed protein was created from the outer N-terminal part (19 aa) and internal C-terminal tail (101–222 aa) of the M protein (YP_009724393.1) and was recombinantly produced and purified. The designed M protein (16,498.74 Da, pI 8.79) revealed both IgM and IgG reactivity with serum samples from COVID-19 convalescents in Western blot. In ELISA, more than 93% (28/30) of COVID-19 sera were positive for IgM detection, and more than 96% (29/30) were positive for specific IgG detection to M protein. Based on the capacity to provoke an immune response and its strong antigenic properties, as shown here, and the fact that it is also involved in the virion entry into host cells, the M protein of the SARS-CoV-2 virus as a good antigen has the potential in diagnostic purposes and vaccine design.
format Online
Article
Text
id pubmed-8125631
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81256312021-05-17 IgM and IgG Immunoreactivity of SARS-CoV-2 Recombinant M Protein Lopandić, Zorana Protić-Rosić, Isidora Todorović, Aleksandra Glamočlija, Sofija Gnjatović, Marija Ćujic, Danica Gavrović-Jankulović, Marija Int J Mol Sci Article Diagnostic evaluation of specific antibodies against the SARS-CoV-2 virus is mainly based on spike (S) and nucleocapsid (N) proteins. Despite the critical functions in virus infection and contribution to the pattern of immunodominance in COVID-19, exploitation of the most abundant membrane (M) protein in the SARS-CoV-2 serology tests is minimal. This study investigated the recombinant M protein’s immunoreactivity with the sera from COVID-19 convalescents. In silico designed protein was created from the outer N-terminal part (19 aa) and internal C-terminal tail (101–222 aa) of the M protein (YP_009724393.1) and was recombinantly produced and purified. The designed M protein (16,498.74 Da, pI 8.79) revealed both IgM and IgG reactivity with serum samples from COVID-19 convalescents in Western blot. In ELISA, more than 93% (28/30) of COVID-19 sera were positive for IgM detection, and more than 96% (29/30) were positive for specific IgG detection to M protein. Based on the capacity to provoke an immune response and its strong antigenic properties, as shown here, and the fact that it is also involved in the virion entry into host cells, the M protein of the SARS-CoV-2 virus as a good antigen has the potential in diagnostic purposes and vaccine design. MDPI 2021-05-07 /pmc/articles/PMC8125631/ /pubmed/34066920 http://dx.doi.org/10.3390/ijms22094951 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lopandić, Zorana
Protić-Rosić, Isidora
Todorović, Aleksandra
Glamočlija, Sofija
Gnjatović, Marija
Ćujic, Danica
Gavrović-Jankulović, Marija
IgM and IgG Immunoreactivity of SARS-CoV-2 Recombinant M Protein
title IgM and IgG Immunoreactivity of SARS-CoV-2 Recombinant M Protein
title_full IgM and IgG Immunoreactivity of SARS-CoV-2 Recombinant M Protein
title_fullStr IgM and IgG Immunoreactivity of SARS-CoV-2 Recombinant M Protein
title_full_unstemmed IgM and IgG Immunoreactivity of SARS-CoV-2 Recombinant M Protein
title_short IgM and IgG Immunoreactivity of SARS-CoV-2 Recombinant M Protein
title_sort igm and igg immunoreactivity of sars-cov-2 recombinant m protein
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125631/
https://www.ncbi.nlm.nih.gov/pubmed/34066920
http://dx.doi.org/10.3390/ijms22094951
work_keys_str_mv AT lopandiczorana igmandiggimmunoreactivityofsarscov2recombinantmprotein
AT proticrosicisidora igmandiggimmunoreactivityofsarscov2recombinantmprotein
AT todorovicaleksandra igmandiggimmunoreactivityofsarscov2recombinantmprotein
AT glamoclijasofija igmandiggimmunoreactivityofsarscov2recombinantmprotein
AT gnjatovicmarija igmandiggimmunoreactivityofsarscov2recombinantmprotein
AT cujicdanica igmandiggimmunoreactivityofsarscov2recombinantmprotein
AT gavrovicjankulovicmarija igmandiggimmunoreactivityofsarscov2recombinantmprotein